ACE2 and infection: Even when virus inoculants were calculated using an alternative virus titering strategy (based on viral ORF1a RT-qPCR instead of Vero E6-ACE2-TMPRSS2 infection (Supplemental Table 1), BA.1 maintained a significant replicative advantage in nasal monolayers relative to WA1 (Supplemental Fig. 2G).